MitoRx Therapeutics, an Oxford, UK-based biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases, raised an undisclosed amount in additional seed funding.
The round, which brought the total amount to $4M, was led by UK Innovation & Science Seed Fund, Wren Capital, Longevitytech.fund, The Fink Family Office, the Science Angel Syndicate Network, Oxford Technology Management, as well as angel investors.
The company intends to use the funds to accelerate its pre-clinical work in HD, the activation of its first neurodegenerative disease program, and to explore research collaborations and partnerships. MitoRX expects to see preclinical readouts in DMD, HD, and COPD, by the end of Q2 2024.
Led by CEO Jon Rees, Chief Development Officer Dr Christine Charman, and Chief Scientific Officer Professor Matt Whiteman of the University of Exeter, MitoRx is a preclinical stage biotechnology company developing orally delivered, mitochondrial protective therapeutics targeting rare neuromuscular disorders and neurodegenerative diseases. Its therapeutic pipeline targets mitochondria dysfunction linked to the progression of rare diseases such as the neuromuscular disorder Duchenne muscular dystrophy (DMD), the neurodegenerative disorder Huntington’s disease (HD), and also implicated in common neurodegenerative diseases.
FinSMEs
14/12/2023